A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 45/00 (2006.01) A61K 47/48 (2006.01) C07K 14/56 (2006.01) C07K 16/00 (2006.01) C07K 16/28 (2006.01) C07K 16/30 (2006.01)
Patent
CA 2412901
The present invention provides a nucleic acid encoding IFN-.alpha. fusion proteins. The specification also describes the proteins encoded by said nucleic acids, methods of making IFN-.alpha. fusion proteins and methods of utilizing the compounds for the treatment of cancer. One specific IFN-.alpha. fusion protein comprising IFN-.alpha. or a portion thereof capable of enhancing the killing ability of an effector cell and an anti-CD20 antibody, such as RITUXAN®, which can target, for example, B cell lymphomas e.g., non-Hodgkin's lymphoma).
L'invention concerne un acide nucléique codant pour des protéines hybrides IFN-.alpha.. L'invention concerne également les protéines codées par lesdits acides nucléiques, des procédés de fabrication de protéines hybrides IFN-.alpha. ainsi que des procédés d'utilisation de ces composés pour le traitement du cancer. L'invention concerne également une protéine hybride IFN-.alpha. spécifique comprenant IFN-.alpha. ou une partie de celui-ci, pouvant améliorer la capacité tueuse d'une cellule effectrice et d'un anticorps anti-CD20, tel que RITUXAN®, lequel peut avoir pour cible, par exemple, des lymphomes cellulaires B (par ex. un lymphome non hodgkinien)
Biogen Idec Inc.
Gowling Lafleur Henderson Llp
Idec Pharmaceutical Corporation
LandOfFree
Bispecific fusion protein and method of use for enhancing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bispecific fusion protein and method of use for enhancing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bispecific fusion protein and method of use for enhancing... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1896956